Scientists at OMRF are seeking individuals diagnosed with Sjögren’s syndrome to participate in a clinical trial for a new drug to treat the condition.
Sjögren’s syndrome causes a person’s immune system to attack the body’s moisture-producing glands, damaging the ability to produce saliva or tears. Common symptoms include dry eyes and dry mouth. The disease can also affect other organs and cause a variety of additional symptoms such as fatigue, arthritis and memory problems.
The trial, sponsored by the National Institutes of Health, will test the effectiveness of an experimental study agent, Baminercept, in treating patients with Sjögren’s syndrome. OMRF scientist Judith James, M.D., Ph.D., will lead the study. James, who holds the Lou C. Kerr Endowed Chair in Biomedical Research, serves as member and chair of OMRF’s Arthritis and Clinical Immunology Research Program.
Individuals between the ages of 18 and 75 previously diagnosed with Sjögren’s may be eligible to participate.